AAM
XENE icon

Advisors Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Advisors Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Sell
5,086
-1,875
-27% -$104K ﹤0.01% 1078
2026
Q1 		$405K Sell
6,961
-1,051
-13% -$48.4K 0.01% 1012
2025
Q4 		$359K Sell
8,012
-3,452
-30% -$145K 0.01% 1025
2025
Q3 		$460K Sell
11,464
-741
-6% -$26.1K 0.01% 988
2025
Q2 		$382K Sell
12,205
-2,076
-15% -$67.7K 0.01% 1000
2025
Q1 		$479K Buy
14,281
+1,233
+9% +$46.8K 0.01% 937
2024
Q4 		$511K Sell
13,048
-544
-4% -$22.5K 0.01% 923
2024
Q3 		$535K Buy
13,592
+493
+4% +$19.9K 0.01% 912
2024
Q2 		$511K Sell
13,099
-618
-5% -$24.7K 0.01% 894
2024
Q1 		$591K Buy
13,717
+3,301
+32% +$152K 0.01% 865
2023
Q4 		$480K Buy
10,416
+228
+2% +$8.06K 0.01% 902
2023
Q3 		$348K Buy
10,188
+2,096
+26% +$78.4K 0.01% 995
2023
Q2 		$312K Sell
8,092
-300
-4% -$11.9K 0.01% 1040
2023
Q1 		$300K Buy
8,392
+546
+7% +$20.2K 0.01% 1041
2022
Q4 		$309K Buy
7,846
+3,725
+90% +$136K 0.01% 1050
2022
Q3 		$149K Sell
4,121
-927
-18% -$33.3K ﹤0.01% 1194
2022
Q2 		$154K Buy
5,048
+2,900
+135% +$87.7K ﹤0.01% 1212
2022
Q1 		$65.7K Buy
+2,148
New +$64.3K ﹤0.01% 1388

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Advisors Asset Management's XENE Position: Q2 2026 in Review

Advisors Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 27% in Q2 2026, selling an estimated $104K and leaving 5,086 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #1078.

Advisors Asset Management first reported a position in XENE in Q1 2022 and has held it in 18 quarters since. The position peaked at $591K in Q1 2024. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Advisors Asset Management held 5,086 shares of Xenon Pharmaceuticals worth $307K as of Q2 2026.
  • Advisors Asset Management sold 1,875 Xenon Pharmaceuticals shares in Q2 2026, an estimated $104K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1078 holding.
  • Advisors Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Advisors Asset Management's Xenon Pharmaceuticals position peaked at $591K in Q1 2024.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.